INMB logo

INmune Bio (INMB) Free Cash Flow

Annual FCF

-$11.98 M
+$10.71 M+47.19%

31 December 2023

INMB Free Cash Flow Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly FCF

-$6.99 M
+$900.00 K+11.41%

30 September 2024

INMB Quarterly FCF Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM FCF

-$25.75 M
-$2.72 M-11.82%

30 September 2024

INMB TTM FCF Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

INMB Free Cash Flow Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+47.2%-63.8%-80.4%
3 y3 years-34.0%+11.8%+28.7%
5 y5 years-481.8%-259.0%-375.6%

INMB Free Cash Flow High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years-34.0%+72.5%-512.3%+28.6%-114.9%+45.5%
5 y5 years-481.8%+72.5%-1511.9%+66.3%-411.7%+45.5%
alltimeall time-3674.4%+72.5%-2024.7%+66.3%-7731.2%+45.5%

INmune Bio Free Cash Flow History

DateAnnualQuarterlyTTM
Sept 2024
-
-$6.99 M(-11.4%)
-$25.75 M(+11.8%)
June 2024
-
-$7.89 M(+5.5%)
-$23.03 M(+25.7%)
Mar 2024
-
-$7.48 M(+119.8%)
-$18.32 M(+52.9%)
Dec 2023
-$11.98 M(-47.2%)
-$3.40 M(-20.2%)
-$11.98 M(-16.1%)
Sept 2023
-
-$4.26 M(+34.3%)
-$14.27 M(+6.7%)
June 2023
-
-$3.17 M(+178.2%)
-$13.38 M(-10.6%)
Mar 2023
-
-$1.14 M(-80.0%)
-$14.96 M(-34.0%)
Dec 2022
-$22.69 M(-47.9%)
-$5.70 M(+69.1%)
-$22.69 M(-15.3%)
Sept 2022
-
-$3.37 M(-29.2%)
-$26.77 M(-14.5%)
June 2022
-
-$4.76 M(-46.3%)
-$31.33 M(-33.7%)
Mar 2022
-
-$8.87 M(-9.4%)
-$47.28 M(+8.7%)
Dec 2021
-$43.50 M
-$9.78 M(+23.4%)
-$43.50 M(+20.5%)
Sept 2021
-
-$7.92 M(-61.7%)
-$36.12 M(+13.2%)
June 2021
-
-$20.71 M(+306.7%)
-$31.89 M(+145.3%)
DateAnnualQuarterlyTTM
Mar 2021
-
-$5.09 M(+112.9%)
-$13.00 M(+45.4%)
Dec 2020
-$8.94 M(+66.1%)
-$2.39 M(-35.3%)
-$8.94 M(+28.0%)
Sept 2020
-
-$3.70 M(+103.4%)
-$6.98 M(+33.5%)
June 2020
-
-$1.82 M(+75.7%)
-$5.23 M(+4.0%)
Mar 2020
-
-$1.03 M(+138.8%)
-$5.03 M(-6.6%)
Dec 2019
-$5.38 M(+161.5%)
-$433.40 K(-77.7%)
-$5.38 M(-0.5%)
Sept 2019
-
-$1.95 M(+20.3%)
-$5.41 M(+38.2%)
June 2019
-
-$1.62 M(+16.6%)
-$3.92 M(+25.7%)
Mar 2019
-
-$1.39 M(+200.1%)
-$3.12 M(+51.4%)
Dec 2018
-$2.06 M(+138.9%)
-$462.40 K(+2.8%)
-$2.06 M(+29.0%)
Sept 2018
-
-$449.90 K(-45.0%)
-$1.60 M(+39.2%)
June 2018
-
-$817.80 K(+148.7%)
-$1.15 M(+248.7%)
Mar 2018
-
-$328.80 K
-$328.80 K
Dec 2017
-$861.80 K(+171.5%)
-
-
Dec 2016
-$317.40 K
-
-

FAQ

  • What is INmune Bio annual free cash flow?
  • What is the all time high annual FCF for INmune Bio?
  • What is INmune Bio annual FCF year-on-year change?
  • What is INmune Bio quarterly free cash flow?
  • What is the all time high quarterly FCF for INmune Bio?
  • What is INmune Bio quarterly FCF year-on-year change?
  • What is INmune Bio TTM free cash flow?
  • What is the all time high TTM FCF for INmune Bio?
  • What is INmune Bio TTM FCF year-on-year change?

What is INmune Bio annual free cash flow?

The current annual FCF of INMB is -$11.98 M

What is the all time high annual FCF for INmune Bio?

INmune Bio all-time high annual free cash flow is -$317.40 K

What is INmune Bio annual FCF year-on-year change?

Over the past year, INMB annual free cash flow has changed by +$10.71 M (+47.19%)

What is INmune Bio quarterly free cash flow?

The current quarterly FCF of INMB is -$6.99 M

What is the all time high quarterly FCF for INmune Bio?

INmune Bio all-time high quarterly free cash flow is -$328.80 K

What is INmune Bio quarterly FCF year-on-year change?

Over the past year, INMB quarterly free cash flow has changed by -$2.72 M (-63.84%)

What is INmune Bio TTM free cash flow?

The current TTM FCF of INMB is -$25.75 M

What is the all time high TTM FCF for INmune Bio?

INmune Bio all-time high TTM free cash flow is -$328.80 K

What is INmune Bio TTM FCF year-on-year change?

Over the past year, INMB TTM free cash flow has changed by -$11.47 M (-80.39%)